- Home
- PIII vs COEP Comparison
PIII vs COEP Comparison
Compare PIII & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- COEP
- Stock Information
- Founded
- PIII 2015
- COEP 2017
- Country
- PIII United States
- COEP United States
- Employees
- PIII N/A
- COEP N/A
- Industry
- PIII Medical/Nursing Services
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PIII Health Care
- COEP Health Care
- Exchange
- PIII Nasdaq
- COEP Nasdaq
- Market Cap
- PIII 21.4M
- COEP 27.4M
- IPO Year
- PIII N/A
- COEP N/A
- Fundamental
- Price
- PIII $6.32
- COEP $9.84
- Analyst Decision
- PIII Buy
- COEP
- Analyst Count
- PIII 2
- COEP 0
- Target Price
- PIII $16.25
- COEP N/A
- AVG Volume (30 Days)
- PIII 3.7K
- COEP 37.4K
- Earning Date
- PIII 08-06-2025
- COEP 08-15-2025
- Dividend Yield
- PIII N/A
- COEP N/A
- EPS Growth
- PIII N/A
- COEP N/A
- EPS
- PIII N/A
- COEP N/A
- Revenue
- PIII $1,485,192,000.00
- COEP $62,874.00
- Revenue This Year
- PIII N/A
- COEP N/A
- Revenue Next Year
- PIII $7.92
- COEP N/A
- P/E Ratio
- PIII N/A
- COEP N/A
- Revenue Growth
- PIII 9.79
- COEP N/A
- 52 Week Low
- PIII $6.00
- COEP $2.31
- 52 Week High
- PIII $32.54
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- PIII 42.33
- COEP 62.24
- Support Level
- PIII $6.00
- COEP $7.25
- Resistance Level
- PIII $6.46
- COEP $9.90
- Average True Range (ATR)
- PIII 0.21
- COEP 0.63
- MACD
- PIII 0.07
- COEP 0.26
- Stochastic Oscillator
- PIII 33.33
- COEP 85.62
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.